HIV fusion and its inhibition.
LaBranche
C C
CC
Department of Surgery, Duke University Medical Center, Durham, NC, USA. celia.labranche@duke.edu
Galasso
G
G
Moore
J P
JP
Bolognesi
D P
DP
Hirsch
M S
MS
Hammer
S M
SM
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001596:Benzylamines; D016860:CD4 Immunoadhesins / Q000494:pharmacology / Q000627:therapeutic use; D000080027:Cyclams; D000077560:Enfuvirtide; D006678:HIV / Q000187:drug effects* / Q000502:physiology; D015700:HIV Envelope Protein gp41 / Q000494:pharmacology / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D006571:Heterocyclic Compounds / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008561:Membrane Fusion / Q000187:drug effects*; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use; D015728:Receptors, HIV / Q000187:drug effects / Q000378:metabolism*
D019380:Anti-HIV Agents; D001596:Benzylamines; D016860:CD4 Immunoadhesins; C096753:CD4-IgG(2); D000080027:Cyclams; D015700:HIV Envelope Protein gp41; D006571:Heterocyclic Compounds; D010446:Peptide Fragments; D015728:Receptors, HIV; D000077560:Enfuvirtide; C088327:plerixafor